Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.

Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

By The Northwire Desk — AI Analysis Apr 28, 2026 · 08:00 VPT · 0.1 VentriPoint Diagnostics Ltd.
Executive Summary
  • Most Recent Event (April 28, 2026): Ventripoint's strategic partner, Lishman Global Inc., submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval.
  • Key Detail: The submission qualified for the NMPA’s "green channel" pathway, an expedited review process for innovative medical technologies.
  • Context: This follows a series of partnership announcements in 2025 and early 2026 (Costa Rica, Canada, US) and was foreshadowed by management comments in February 2026 regarding "discussions for China market entry."
  • Technology: VMS+™ 4.0 uses Knowledge Based Reconstruction to provide MRI-equivalent volumetric measurements using standard 2D echocardiography.
  • Previous News Flow (Jan-Apr 2026):
    • April 20: Gold Edison Award for VMS+™ 4.0 technology.
    • March/April: Partnerships with Montecristo Group (Costa Rica), First Light Health (Canada Indigenous communities), and LG Consulting Solutions (Northern California).
    • January: Closed $1M non-brokered private placement; issued shares for debt settlement ($427k) and interest payments.
    • Late 2025: Appointed CFO David Swetlow; announced Device-as-a-Service (DaaS) model shift; secured Providence Health Care Ventures collaboration.
Material Impact
  • Positive Validation: The "green channel" qualification reduces regulatory timeline risk in China, a market cited as having 330 million potential patients. This validates the technology's innovation status with Chinese regulators.
  • Expected Progression: This news fulfills prior guidance given in February 2026 regarding China entry discussions. It does not represent an unexpected commercial breakthrough but rather a procedural milestone in a known expansion strategy.
  • Execution Risk Remains High: Submission is not approval. Commercialization relies on Lishman Global Inc., a third-party partner, introducing dependency risk. No revenue impact is immediate upon submission.
  • Market Reaction Context: Despite a steady stream of positive operational news (awards, partnerships) since late 2025, the stock price has trended downward from $0.17 to $0.10. This suggests the market remains skeptical about capital efficiency and revenue realization despite regulatory progress.
  • Conclusion: The news is fundamentally positive for long-term strategy but does not materially alter the immediate investment thesis given the lack of approval certainty and ongoing dilution.
VPT · Price
Company Overview
  • Company: Ventripoint Diagnostics Ltd. develops AI-powered cardiac imaging software.
  • Flagship Product: VMS+™ 4.0 system. Converts standard 2D echocardiograms into MRI-equivalent 3D volumetric models.
  • Technology: Proprietary Knowledge Based Reconstruction (KBR) and artificial intelligence.
  • Market Position: Targets cost-effective, scalable imaging for congenital heart defects, heart failure, and valvular disease. Claims to reduce reliance on expensive cardiac MRIs.
  • Regulatory Status: FDA cleared (Feb 2025), Health Canada licensed, EU MDR certified. NMPA submission pending (China).
Read the original news release →

More from VentriPoint Diagnostics Ltd.

Jun 26, 2026 · 08:10

AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.

M&A / Property Jun 16, 2026 · 09:11

AI cardiac imaging startup scales commercial partnerships but remains cash-constrained and pre-revenue at scale.

Other Apr 20, 2026 · 08:50

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Other Apr 16, 2026 · 11:00

TSXV Venture Exchange Listed Cardiac Imaging Platform

M&A / Property Apr 01, 2026 · 22:50

Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

M&A / Property Mar 27, 2026 · 10:15

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

M&A / Property